▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / BMY

BMY — BRISTOL MYERS SQUIBB CO

—
NYSE · Health Care · Pharmaceuticals · CIK 14272 ·
Last close
$57.52
Market Cap
$117.46B
52W High
$61.59
52W Low
$53.44
ADV30
13,011,767
Next earnings
2026-07-30
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 11,489,000,000 8,068,000,000 3,365,000,000 2,677,000,000 86,476,000,000 9,574,000,000 66,374,000,000
Dec 2025 12,503,000,000 8,406,000,000 2,813,000,000 1,087,000,000 90,038,000,000 10,209,000,000 71,532,000,000
Sep 2025 12,222,000,000 8,787,000,000 3,639,000,000 2,201,000,000 96,889,000,000 15,726,000,000 78,289,000,000
Jun 2025 12,269,000,000 8,897,000,000 3,774,000,000 1,310,000,000 94,676,000,000 12,599,000,000 77,187,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,306,000,000
Investing CF
$-3,764,000,000
Financing CF
$-10,915,000,000
CapEx
$-1,398,000,000
Dividends Paid
$-5,070,000,000
Buybacks
$0
EPS Diluted TTM
$3.56
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$18,287,000,000
Inventory
$2,756,000,000
Receivables
$12,083,000,000
ST Investments
$912,000,000
EBIT TTM
$11,405,000,000
Pretax Income TTM
$9,597,000,000
Interest Exp TTM
$1,808,000,000
Analysts
25

Yahoo Snapshot (yfinance, live)

Total Revenue
$48,482,000,896
EBITDA
$18,973,999,104
Free Cash Flow
$9,851,750,400
Enterprise Value
$153,436,930,048
Total Cash
$10,485,999,616
Total Debt
$46,428,999,680
Shares Out
2,042,071,247
Trailing EPS
$3.57
Book Value
$9.83
ROE
38.7%
ROA
10.7%
Div Yield
4.38%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 48,195,000,000 13,724,000,000 7,054,000,000 90,038,000,000 71,532,000,000 — 14,156,000,000
Dec 2024 48,300,000,000 5,887,000,000 -8,948,000,000 92,603,000,000 76,215,000,000 — 15,190,000,000
Dec 2023 45,006,000,000 8,195,000,000 8,025,000,000 95,159,000,000 65,674,000,000 — 13,860,000,000
Dec 2022 46,159,000,000 9,104,000,000 6,327,000,000 96,820,000,000 65,702,000,000 — 13,066,000,000

TTM Snapshot

Revenues TTM
$45,700,000,000
NetIncome TTM
$6,291,000,000
OpCashFlow TTM
$0
Assets (Latest)
$92,603,000,000
Forward EPS
$6.17

Max Pain — expiry 2026-07-02

max pain strike: $59.00 · spot: $57.60 · call oi: 7,377 · put oi: 11,370
Expected Move to 2026-07-02: ±$1.78 (3.08%) — implied range $55.82 – $59.37 · ATM straddle on $58.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VRTX VERTEX PHARMACEUTICALS INC / MA $124.70B $491.34 —
GSK GSK plc $105.17B $52.50 —
SNY Sanofi $102.81B $42.95 —
SNYNF Sanofi $101.95B $85.18 —
GLAXF GSK plc $101.49B $25.33 —

News headlines (Yahoo Finance, 1h cache)

66 With $1.3 Million. Here Are 3 Hidden Gems to Target
2026-06-29 14:51 · Yahoo
Establishment Labs® Appoints Taylor Harris to Board of Directors
2026-06-29 12:00 · Yahoo
AbbVie Stock's Growth Story Has One Question Mark
2026-06-26 16:03 · Yahoo
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-26 15:50 · Yahoo
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
2026-06-25 13:10 · Yahoo
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
2026-06-25 12:15 · Yahoo
Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI
2026-06-25 12:15 · Yahoo
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb
2026-06-25 04:26 · Yahoo
A $30 Billion Cancer Breakthrough Is Under Threat From Global Conflicts
2026-06-24 21:00 · Yahoo
The Number That Could Test AbbVie Stock
2026-06-24 19:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →